Inloggad som:
CARTITUDE-5
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
CARTITUDE-5
En studie som jämför bortezomib, lenalidomid och dexametason och efterföljande cilta-cel-behandling (en CAR-T-behandling riktad mot BCMA) med bortezomib, lenalidomid och dexametason och efterföljande lenalidomid och dexametason-behandling hos patienter med nydiagnosticerad multipelt myelom
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Skånes universitetssjukhus / Hematologisk vård
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Mer information om studien för vårdgivare
Documented diagnosis of multiple myeloma (MM) according to International Myeloma Working Group (IMWG) diagnostic criteria
Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=)1.0 gram (se länk för mer info)
Frailty index of >=2 according to Myeloma Geriatric Assessment score
Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5 (se länk för mer info)
Behandling
Fas 3
Kurativ
Ej tillämpbar
Företag
Studien ändrades senast: (2025-10-13)